Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) (FF:PV3), a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

“We are very encouraged by the additional data presented at the Angiogenesis 2010 meeting and look forward to the upcoming NDA filing for potentially the first ophthalmic drug therapy approved for DME”

Peter A. Campochiaro, MD, of The Johns Hopkins University School of Medicine, presented the 24-month results from the FAME study at the Angiogenesis 2010 meeting in Miami based on analysis of the Full Analysis Set representing all randomized patients. As previously reported, the difference in the percentage of patients in this dataset whose best corrected visual acuity (BCVA) improved by 15 or more letters from baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at month 24 was statistically significant for both doses of Iluvien in each of the two trials composing the FAME Study as well as on a combined basis. For the combined analysis, 28.7% of patients treated with low dose Iluvien, and 28.6% of patients treated with high dose gained at least 15 letters, compared with 16.2% of control patients, p = 0.002 for high and low dose. Based on the 24-month data, Alimera previously announced that it intends to file a New Drug Application (NDA) for regulatory approval of the Iluvien low-dose in Q2 calendar 2010.

Among the new efficacy data reported by Dr. Campochiaro, over 50% of Iluvien low dose patients gained at least 5 letters at 24 months. Further, over 75% of the Iluvien low dose patients received only a single administration of Iluvien. Over one-third of the one-administration patients with 24 month data gained more than 15 letters at 24 months.

Patients receiving low dose Iluvien were also less likely to receive additional treatments for their DME. During the 24-month period, almost twice as many patients in the control group received laser treatment compared to the low dose Iluvien patients (58.9% of control versus 36.7% of low dose Iluvien), and more than twice as many patients in the control group received an off-protocol treatment (intravitreal injection of Kenalog® or LUCENTIS® or Avastin® or vitrectomy) compared to patients in the low dose Iluvien group (28.6% of control versus 12.5% of low dose Iluvien).

Also reported was additional safety data. As previously reported patients receiving low dose Iluvien were more likely to have increased intraocular pressure. The new data showed that patients receiving low dose Iluvien were also slightly more likely to develop glaucoma (deemed serious by the reporting physician) than control patients (2.7% of low dose Iluvien versus 1.1% of control). Low dose Iluvien patients also experienced slightly lower rates of retinal detachment (0.5% of low dose Iluvien versus 1.6% of control) and vitreous hemorrhage (2.1% of low dose Iluvien versus 2.7% of control) deemed serious by the reporting physician.

Cataracts, which can generally be corrected with standard cataract surgery, occur more commonly in patients with DME and in patients receiving steroids. In the FAME study approximately one third of patients had cataract surgery before they entered the trial. Of the remaining patients, those randomized to Iluvien low dose were approximately twice as likely to develop cataract as those randomized to control (over 80% of low dose Iluvien versus approximately 45% of control) and approximately three times more likely to have cataract surgery than control patients (75% of low dose Iluvien versus 23% of control).

“We are very encouraged by the additional data presented at the Angiogenesis 2010 meeting and look forward to the upcoming NDA filing for potentially the first ophthalmic drug therapy approved for DME," said Dr. Paul Ashton, President and CEO of pSivida.

The FAME study, conducted at 101 sites in North America, Europe and India, enrolled 956 patients in two randomized, double-masked, parallel groups to study Iluvien for treatment of diabetic macular edema. The enrollees were randomized in a 2:2:1 (two received the high dose Iluvien; two received the low dose Iluvien; and one received a sham procedure). The primary efficacy endpoint for the FAME Study is the difference in the percentage of patients whose BCVA improved by 15 or more letters from baseline on the ETDRS eye chart at month 24 between the treatment and control groups. In the trials, at the physicians’ discretion, patients were allowed to receive additional administrations of Iluvien after 12 months of follow-up, and additional laser treatments 6 weeks after randomization.

In the Full Analysis Set of all randomized patients used to analyze the overall efficacy data for the Angiogenesis presentation, if 24 month data was missing it was imputed from the last available observation. At 24 months, 22.7% of patients in the control group had discontinued the trial or were unavailable for follow up compared to 19.9% of the low dose Iluvien patients. As a result, the amount of imputed data are approximately the same in the treatment and control groups (approximately 20% in each group) utilizing the Full Analysis Set.

Other analyses of the data performed by protocol, which were previously reported, included a Modified ART analysis of all patients randomized and treated, which was specified as the primary method for assessing efficacy in the protocol. In the Modified ART analysis, in addition to imputing 24-month data that was missing, 24 month data was also imputed if a patient had an off-protocol treatment. In the Modified ART analysis therefore approximately 50% of the control data and approximately 30% of the Iluvien low dose data was imputed. The Modified ART analysis was the only dataset of the three analyses performed that did not achieve statistical significance for low dose Iluvien.

Following the recent release of the top-line two year data from the FAME Study, Alimera raised $10 million from its investors via the exercise of warrants. Alimera is due to begin monthly principal payments of $500,000 to pSivida plus quarterly interest payments at 20% annually based on a $15 million contingent note in April 2010.